The Covid-19 pandemic has wreaked havoc across the globe — including upending the process of drug development.
That has been especially true in clinical trials for oncology, which come with a complex set of considerations. Patients often have to come into the clinic or be hospitalized for treatment. They also have to be protected against possible infections that could devastate a weakened immune system.
About the Author Reprints
